Manufacturer record
Welcure Remedies: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
6 batches manufactured by Welcure Remedies (Himachal Pradesh) were declared Not of Standard Quality between January 2019 and June 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: WADG25002A, Adenosine Injection IP 6 mg/2ml (exp Sep 2027). CDTL, Mumbai (CDSCO lab) found it not of standard quality: The sample is not of standard quality as per I.P. 2022 with respect to the Test for Identification, Particulate matter, Sterility, Bacterial. Listed in the June 2026 alert.
Records by type
6 records linked to Welcure Remedies in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Adenosine Injection IP 6 mg/2ml | Batch WADG25002AMfg Oct 2025 · Exp Sep 2027 | The sample is not of standard quality as per I.P. 2022 with respect to the Test for Identification, Particulate matter, Sterility, Bacterial endotoxins, Assay/content of Adenosine and is also not of standard quality for the reasons stated under DescriptionAssay | CDTL, MumbaiCDSCO lab | Jun 2026 |
| Adenosine Injection IP 6 mg/2ml | Batch WADG25001AMfg Aug 2025 · Exp Jul 2027 | The sample does not conforms to I.P. 2022 with respect to the Test of Identification, Particulate matter, Sterility, Bacterial endotoxins and Assay. The sample is deemed spurious as per D and C Act section 17 (B).Assay | CDTL, MumbaiCDSCO lab | Jun 2026 |
| Cefixime (Anhydrous) | Batch WCD24036AMfg May 2024 · Exp Apr 2026 | Content of Cefixime and DescriptionDescription | SDT&RL, BhubaneswarState lab | Mar 2026 |
| Moxiion-CV Dry Syrup (Amoxycillin & Potassium Clavulanate Oral Suspension), 3.3gm/30ml. with water | Batch WJD-092CMfg Aug 2021 · Exp Jan 2023 | Assay/ Content? of Clavulanic AcidAssay | RDTL GuwahatiState lab | Dec 2022 |
| Cefpodoxime Proxetil Dispersible Tablets 200 mg (POME 200 TABLETS) | Batch WJT-175JMfg Aug 2021 · Exp Jul 2023 | Disintegration TestDisintegration | RDTL ChandigarhCDSCO lab | Dec 2021 |
| Invumox-625 (Amoxycillin & Potassium Clavulanate Tablets I.P.) | Batch WFT-170DMfg Dec 2017 · Exp May 2019 | Dissolution and Uniformity of Content of Potassium ClavulanateDissolution | CDL KolkataCDSCO lab | Jan 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.